Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer

Qingli Li, Xiaojiao Cheng, Cong Zhou, Yaoliang Tang, Fuli Li, Baiwen Zhang, Tinglei Huang, Jianzheng Wang, Shuiping TuFrontiers in Oncology 2022 · DOI

TL;DR

This study demonstrates that combining the anti-angiogenic drug fruquintinib with anti-PD-1 immunotherapy significantly enhances anti-tumor responses in microsatellite-stable colorectal cancer (MSS-CRC) models. This combination works by reprogramming the tumor microenvironment, reducing angiogenesis, and boosting the infiltration of anti-tumor immune cells, offering a promising new therapeutic strategy for this challenging cancer type.

What Problem Does This Paper Address?

Colorectal cancer (CRC) remains a significant cause of cancer-related death worldwide. While immunotherapies targeting the PD-1 pathway have shown success in a subset of CRC patients with high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR), their efficacy is limited in the majority of patients with microsatellite-stable (MSS) CRC. This lack of response in MSS-CRC is a major clinical challenge. The paper investigates a potential solution by exploring the combination of fruquintinib, a drug that inhibits angiogenesis (the formation of new blood vessels that tumors need to grow), with anti-PD-1 therapy. The hypothesis is that by normalizing tumor vasculature and reducing immunosuppression, this combination could overcome resistance to PD-1 blockade in MSS-CRC.

Methods

The researchers employed a multi-pronged approach:

  • In Vivo Mouse Models: They used syngeneic mouse models of colorectal cancer (MC38 and CT26 cell lines) to represent both MSS and MSI CRC. These models were treated with fruquintinib alone, anti-PD-1 antibody (sintilimab) alone, or the combination.
  • Tumor Growth and Survival Analysis: Tumor volume and overall survival were meticulously monitored to assess treatment efficacy.
  • Immune Cell Profiling: Flow cytometry was used to analyze immune cell populations in peripheral blood, spleen, and tumor tissues. This included quantifying CD8+ T cells, their cytokine production (TNFα, IFNγ), and myeloid-derived suppressor cells (MDSCs).
  • Angiogenesis Assessment: Immunofluorescence and ultrasound angiography were used to evaluate the impact of fruquintinib on tumor vascularization.
  • Histopathology: Histological analysis of major organs was performed to assess the safety and potential toxicity of the combined treatment.
  • Clinical Case Study: The study also included a retrospective analysis of five MSS-CRC patients who received the combination therapy after failing other treatments.

Datasets

The study utilized:

  • Murine Colorectal Cancer Cell Lines: MC38 and CT26 cell lines were used to establish tumor models.
  • Animal Models: C57BL/6J and BALB/c mice were used for in vivo experiments.
  • Human Patient Data: Data from five MSS-CRC patients treated with the combination therapy were analyzed retrospectively.

Key Insights and Ideas

  • Synergistic Anti-Tumor Effect: The combination of fruquintinib and anti-PD-1 antibody demonstrated a significantly stronger inhibition of tumor growth and prolonged survival compared to either agent alone in both MSS and MSI mouse models.
  • Reprogramming the Tumor Microenvironment: The combination therapy effectively reduced tumor angiogenesis and normalized the tumor vasculature. This, in turn, led to a significant increase in the infiltration of cytotoxic CD8+ T cells, including those producing TNFα and IFNγ, which are crucial for killing cancer cells.
  • Reducing Immunosuppression: The combined treatment also effectively reduced the presence of immunosuppressive cells like MDSCs and macrophages within the tumor microenvironment.
  • Low-Dose Fruquintinib Efficacy: The study suggests that a lower dose of fruquintinib might be sufficient to achieve these beneficial immunomodulatory effects when combined with anti-PD-1 therapy.
  • Clinical Promise: Preliminary clinical data from five refractory MSS-CRC patients showed promising results, with three patients achieving partial response (PR) and two achieving stable disease (SD), indicating the potential for this combination in human patients.
  • Safety Profile: The combination therapy was well-tolerated in mice, with no significant toxicity observed in major organs, and appeared to be safe in the limited patient cohort.

Key Results

  • The combination of fruquintinib and sintilimab achieved the strongest inhibition of tumor growth and the longest survival times in both MC38 and CT26 xenograft tumor models.
  • The combination significantly increased the infiltration of CD8+ T cells, CD8+TNFα+ T cells, and CD8+IFNγ+ T cells in tumor tissues (p<0.05).
  • The combination significantly reduced the ratios of MDSCs and macrophages in mice.
  • Fruquintinib suppressed tubular formation in HUVECs in vitro and reduced tumor vascular formation in CT26 allograft tumor models in vivo.
  • In the clinical study, three out of five MSS-CRC patients achieved partial response (PR), and two achieved stable disease (SD), resulting in a 100% disease control rate.

Limitations and Future Work

The authors acknowledge several limitations:

  • Mouse Models: The study relies on mouse models, which may not perfectly recapitulate the complexity of human colorectal cancer and its tumor microenvironment.
  • Retrospective Clinical Data: The clinical data is from a small, retrospective case series and not a prospective clinical trial.
  • Limited Patient Cohort: The small number of patients limits the generalizability of the clinical findings.

Future work should focus on:

  • Larger Prospective Clinical Trials: Conducting larger, randomized, prospective clinical trials is essential to validate these findings and establish the efficacy and safety of the combination therapy in a broader MSS-CRC patient population.
  • Further Mechanistic Studies: Deeper investigation into the precise molecular mechanisms by which fruquintinib reprograms the immune microenvironment and synergizes with anti-PD-1 therapy is warranted.
  • Optimizing Dosing and Scheduling: Further studies could explore optimal dosing and scheduling of the combination therapy to maximize efficacy and minimize potential side effects.

Summary updated

Abstract

Our results show that the combination of fruquintinib and sintilimab greatly inhibits CRC growth by altering tumor immune microenvironment. This study provides the rational for using the combination of fruquintinib and anti-PD-1 antibody for the treatment of advanced CRC.
BibTeX
@inproceedings{li2022fruquintinib,
  author = {Qingli Li and Xiaojiao Cheng and Cong Zhou and Yaoliang Tang and Fuli Li and Baiwen Zhang and Tinglei Huang and Jianzheng Wang and Shuiping Tu},
  title = {{Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer}},
  booktitle = {Frontiers in Oncology},
  year = {2022},
  doi = {10.3389/fonc.2022.841977},
}
Figure